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Background: Extended smoking cessation follow-up after hospital discharge significantly increases abstinence.
Hospital smoke-free policies create a period of ‘forced abstinence’ for smokers, thus providing an opportunity to
integrate tobacco dependence treatment, and to support post-discharge maintenance of hospital-acquired
abstinence. This study is funded by the National Heart, Lung, and Blood Institute (1U01HL1053231).
Methods/Design: The Inpatient Technology-Supported Assisted Referral study is a multi-center, randomized clinical
effectiveness trial being conducted at Kaiser Permanente Northwest (KPNW) and at Oregon Health & Science
University (OHSU) hospitals in Portland, Oregon. The study assesses the effectiveness and cost-effectiveness of
linking a practical inpatient assisted referral to outpatient cessation services plus interactive voice recognition
(AR + IVR) follow-up calls, compared to usual care inpatient counseling (UC). In November 2011, we began
recruiting 900 hospital patients age ≥18 years who smoked ≥1 cigarettes in the past 30 days, willing to remain
abstinent postdischarge, have a working phone, live within 50 miles of the hospital, speak English, and have no
health-related barriers to participation. Each site will randomize 450 patients to AR + IVR or UC using a 2:1
assignment strategy. Participants in the AR + IVR arm will receive a brief inpatient cessation consult plus a referral to
available outpatient cessation programs and medications, and four IVR follow-up calls over seven weeks
postdischarge. Participants do not have to accept the referral. At KPNW, UC participants will receive brief inpatient
counseling and encouragement to self-enroll in available outpatient services. The primary outcome is self-reported
thirty-day smoking abstinence at six months postrandomization for AR + IVR participants compared to usual care.
Additional outcomes include self-reported and biochemically confirmed seven-day abstinence at six months, self-
reported seven-day, thirty-day, and continuous abstinence at twelve months, intervention dose response at six and
twelve months for AR + IVR recipients, incremental cost-effectiveness of AR + IVR intervention compared to usual
care at six and twelve months, and health-care utilization and expenditures at twelve months for AR + IVR recipients
compared to UC.
Discussion: This study will provide important evidence for the effectiveness and cost-effectiveness of linking
hospital-based tobacco treatment specialists’ services with discharge follow-up care.
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How health-care facilities treat tobacco dependence in
patients with cardiac and pulmonary diagnoses is a
quality-of-care measure that ultimately affects whether
facilities meet accreditation standards [1]. The Joint
Commission recently expanded the requirement that
health-care facilities also treat tobacco dependence to
patients with other diagnoses, and broadened the
requirements for what constitutes effective treatment
[2,3]. Efforts to establish tobacco cessation as an element
of treatment required to meet inpatient standards of
care capitalizes on the forced abstinence that occurs
with a hospital stay in a smoke-free facility. Hospital
stays can also potentially increase smokers’ motivation to
remain quit if their illness and hospitalization is smoking-
related. Previous research has shown that initiating profes-
sional treatment during this ‘teachable moment’, and
providing patients with multiple intervention contacts
after discharge, leads to significant increases in quit rates
[3-10]. Smokers with four or more weeks of cessation sup-
port postdischarge are more likely to be abstinent after a
year compared to those without support [7].
Creating an integrated clinical pathway—from in-
patient assistance to outpatient cessation services—is
challenging for any health-care delivery system, even
closed-model HMOs that provide inpatient services as
well as outpatient clinical care and behavior-change ser-
vices. An effective model includes in-hospital treatment
by trained professionals whose primary responsibility is
tobacco cessation [10] and a hospital-managed follow-up
program for continuity of care [11]. With the growing
use of electronic medical records (EMR) to support
medical decisions and document care, any tobacco-
cessation model also should be able to establish an inte-
grated clinical pathway, from admission through dis-
charge instructions and follow-up, for health providers
to order and document treatment and referrals. Integrat-
ing inpatient and outpatient cessation services is much
more daunting for free-standing and academic hospitals
that serve patients who are potentially covered by
dozens of health insurance plans. Typically, insurance
plans will cover inpatient services but prior authorization
is needed for outpatient coverage. Creating an effective
hospital-initiated treatment program requires an innova-
tive solution to bridge the gap from inpatient to ef-
fective outpatient care that lasts at least four weeks
postdischarge.
This paper describes the protocol for the Inpatient
Technology-Supported Assisted Referral (I-TSAR)
study. This randomized controlled trial evaluates the
effectiveness and cost-effectiveness of an approach for
initiating and integrating tobacco treatment into hos-
pital care and continuing follow-up care for patients ad-
mitted to Kaiser Permanente Northwest (KPNW) andOregon Health & Science University (OHSU) hospitals.
This intervention uses existing electronic medical records
systems and tobacco treatment specialists (TTS) (nurses
and/or health educators) to identify smokers and deliver
effective components of hospital-initiated treatment; pro-
vide proactive assisted referrals to available outpatient
counseling programs and medications; and link patients
to an innovative interactive voice recognition (IVR) tele-
phone follow-up system. IVR follow-up represents a prom-
ising method for efficient postdischarge follow-up for
treatment plans initiated during hospitalization [12-14].
Combining tobacco treatment expertise with health-system
technology can help address many of the existing problems
with integrating in-hospital tobacco-dependence treatment
and cost-effective outpatient follow-up care.Methods/Design
This is a multicenter, randomized usual care-controlled
clinical effectiveness trial conducted with patients admit-
ted to two large hospitals serving the Portland, Oregon
and southwest Washington metropolitan area. We will
randomize 900 participants to receive either an inpatient
assisted referral for postdischarge tobacco-cessation ser-
vices plus interactive voice recognition support (AR+
IVR) or usual care (UC). This study is one of six studies
funded by the National Institutes of Health (NIH) that
make up the Consortium of Hospitals Advancing Re-
search on Tobacco (CHART). The study was approved
by the Institutional Review Board (IRB) of each partici-
pating institution, and all participants provide written
informed consent. The CHART Data Safety Monitoring
Board (DSMB) also reviewed and approved the study.Setting
Participants will be recruited from KPNW Sunnyside
Medical Center and OHSU hospital in Portland, Oregon.
KPNW is a federally qualified, not-for-profit HMO serv-
ing more than 470,000 members in northwest Oregon
and southwest Washington through one hospital and 26
medical offices. It is an integrated, group-model health-
delivery system that provides and coordinates the entire
scope of care for its members, including access to a
range of tobacco-cessation services through its Health
Education Department. Existing inpatient tobacco-
cessation services encourage patients with pneumonia,
chronic heart failure, and ischemic heart disease to quit
and enroll in cessation services upon discharge. OHSU
is an academic health center serving a multistate area
with specialty tertiary health-care services. OHSU has an
existing inpatient tobacco-cessation consult service pro-
vided to patients referred by hospital staff: the service
includes encouragement to use outpatient cessation ser-
vices and a single follow-up call shortly after discharge.
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and have established tobacco-free campuses. In 2010,
the Oregon legislature mandated that all Oregon com-
mercial health insurance plans provide a $500 benefit
for tobacco-cessation counseling and FDA-approved
medications. Oregon’s Medicaid program already pro-
vides comprehensive coverage.
Population
The study population consists of adult patients age ≥18
years admitted to KPNW or OHSU hospitals who have
smoked a cigarette (even a puff ) within the past 30 days,
speak English, have a working telephone, are interested
in attempting to remain abstinent from smoking post-
discharge, and can participate in the informed consent
process. Patients must also live within 50 miles of the
hospital and be willing to attend an in-person follow-upTable 1 Characteristics of likely eligible smokers discharged f
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Discharge data also show that smokers were somewhat more likely to be male. Thuvisit at six months. Patients are excluded from the study
if they are admitted to a critical care, labor/delivery, or
psychiatric unit, are pregnant or breastfeeding, have ac-
cess restrictions (for example, MRSA), are physically too
ill to participate in a research study (that is, cannot
complete a six-month follow-up), or are cognitively un-
able to provide informed consent. Patients with a history
of mental illness are included if admitted to nonpsychia-
tric units.
The eligibility requirements well represent the popula-
tion of hospitalized current smokers and very recent
quitters who meet the Joint Commission targeted patient
population. The Joint Commission’s tobacco treatment
standards apply to all patients regardless of diagnosis,
except the cognitively impaired [2], who would likely be
interested in services to help them remain abstinent
after they leave the hospital, and could benefit fromrom KPNW and OHSU hospitals in 2010
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phone follow-up. The exceptions to this standard in-
clude women in labor/delivery units and patients who
are unlikely to attend a six-month in-person follow-up
assessment visit. This and other CHART studies define
smoking eligibility as having smoked at least one
cigarette in the last thirty days. This commonly used def-
inition recognizes the likelihood that many patients may
report quitting smoking even though they may have
stopped within the couple of weeks prior to admission.
The TTS will postpone a consult visit if a patient cannot
speak, is heavily medicated, in obvious pain, or has
restricted access. In some instances, we expect the TTS
EMR review to indicate that a patient is too physically ill
to participate, for example, the patient is documented
with a severely life-limiting condition or is to be dis-
charged to hospice care.
Administrative data show that more than 5,000 current
adult smokers meeting the above eligibility requirements
are discharged each year from KPNW and OHSU hospi-
tals (Table 1). The demographic characteristics of dis-
charged smokers are similar between the two sites.
Ethnicity and race are routinely collected at hospital ad-
mission at both institutions, although KPNW only re-
cently began collecting this information. In 2010, data
indicate that hospitalized smokers were predominantly
non-Hispanic and white. According to the 2010 Census
data, about 19.5% of the Portland, Oregon metropolitan
area served by Kaiser Permanente and OHSU is of either
non-white or mixed race and 10.9% are of Hispanic eth-
nicity. Consequently, our study will over-recruit Hispanic
and other minorities in order to match the demographics
of the surrounding community.Recruitment
Participant recruitment involves an initial prescreening
process using electronic administrative and medical
records data at each site, followed by an in-person
screening by the TTS at each site for patients who ap-
pear eligible during EMR prescreening. The EMR pre-
screening process allows the TTS to efficiently identify
likely eligible patients and review relevant medical his-
tories before an in-person consultation. The recruitment
process is reflected in the I-TSAR consort diagram
(Figure 1).
We will need to recruit about 12% of the estimated
6,250 adult smokers who meet our eligibility criteria in
order to meet our recruitment target of 900 smokers
over 15 months. Our experience with patient popula-
tions suggests that 50% or more of identified smokers
will meet the study criteria and be interested in trying to
quit [10], and 50% or more of these patients will be
interested in participating in the study [3,9,10,15]. Thus,if we underachieve our recruitment goal by half we will
still meet our recruitment target.
We expect a high follow-up rate for six- and twelve-
month assessments. Studies of KPNW and OHSU
patients typically achieve follow-up rates of 85% and
above for clinical studies [10,15-17]. Each site employs
experienced recruitment staff who use electronic track-
ing systems that collect and maintain up-to-date sched-
uling and contact information, notification of upcoming
follow-up encounters, and web- and phone-based quer-
ies for missing addresses.
EMR prescreening
Each morning, information for admitted patients is cap-
tured from the EMR and downloaded into an electronic
report used for prescreening. Patients are excluded if
they are currently under age 18, have no recent smoking
history, are located in one of the excluded units, or have
already been screened for the study. Since the number of
eligible smokers per day is likely to exceed the capacity
of study staff, an algorithm is used to create a daily con-
tact list that objectively assigns patients a contact order
(1-n) for in-person screening and recruitment. The algo-
rithm also incorporates recruitment targets for Hispa-
nics, racial minorities, and females. Once the contact list
is generated, the TTS reviews electronic records for add-
itional exclusions. Decision making for physical and cog-
nitive exclusions is guided by nurse and physician scope
of practice at each site. The remaining prescreened eli-
gible patients are contacted by the TTS for additional
screening and recruitment is conducted as part of a
tobacco-cessation consult. Patients on the contact list
who are not seen by a TTS are re-prioritized the next
day if they are still hospitalized.
In-person screening and baseline assessment
All patients contacted and willing to discuss tobacco use
are provided a brief tobacco-cessation consult (see usual
care description below). The TTS conducts face-to-face
screening to confirm eligibility, assess interest in partici-
pation, conduct informed consent procedures, complete
a baseline assessment, and randomize participants to the
AR+ IVR or UC groups.
Randomization
Randomization is conducted using a selection and docu-
mentation procedure that ensures balanced enrollment
over time, blinds the TTS to the assignment, and pre-
vents postrandomization assignment changes. Each site
randomly assigns 450 patients on a 2:1 ratio (300 AR+
IVR: 150 UC) using secure, preprinted, sequentially
numbered randomization envelopes. The study statisti-
cian developed a randomization algorithm using a prede-
termined randomization sequence with permuted blocks
Figure 1 I-TSAR consort diagram.
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all except the data coordinating center (DCC) statistician
and programmer. This strategy ensures balanced enroll-
ment over time and eliminates the ability of the TTS to
guess assignment prior to randomization.
The randomization algorithm matches group assign-
ment to a four-digit randomization number, where the
first digit is the site ID (KP = 1; OHSU= 2) and the last
three digits are the randomization sequence number.
The randomization number is printed on a label and
affixed to the outside of each randomization envelope.
Inside each envelope are two identical self-adhesivelabels printed with the randomization number and treat-
ment arm assignment. The labels are used to confirm
and track randomization. The envelopes are placed in a
box in ascending order. The treatment arm assignment
is not discernable from the outside of the sealed
envelope.
Once a patient is prescreened eligible, the TTS selects
the next randomization envelope in sequence, along with
other patient enrollment forms, and proceeds to the
patient’s room. After the eligible patient provides informed
consent and completes baseline assessment, the TTS opens
the randomization envelope and records the participant’s
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randomization labels to the site’s randomization log, and
then records the date and time of randomization, the par-
ticipant ID number, and the TTS’ initials on the log. A sec-
ond label is affixed to the enrollment checklist form before
transmission to data entry staff. At the OHSU site, the
TTS opens the randomization envelope, places one of the
randomization labels in the patient’s research chart,
records the date and time of randomization, participant
ID number, and the TTS’ initials. A second label is affixed
to the enrollment checklist before transmission to KP data
entry staff.
Randomization fidelity is monitored regularly by com-
paring information from the randomization log, prescre-
ening priority list, and the consult and enrollment
checklists. The fidelity review process involves compari-
sons of participants’ randomization dates and times,
group assignments, and predetermined randomization
numbers. Any unexpected deviation will be reported to
the study principal investigator. Participant assignment
fidelity is maintained during the study by restricted ac-
cess to the file service containing randomization data to
the study statistician and data analyst. Study investiga-
tors and follow-up staff are blinded to treatment group
data.
All randomized patients will be included in the
intention-to-treat analysis of the primary outcome. We
use a 2:1 assignment strategy to increase the number of
AR+ IVR recipients in order to enhance analyses of an
expected dose-effect on outcome, particularly for AR+
IVR participants. The 2:1 assignment strategy also fits our
respective health system’s interest in maximizing the po-
tential treatment benefits to study participants, which is
important to increase cooperation among institutions in
the study and helps build organizational interest in im-
proving cessation services. We do not stratify recruitment
on population characteristics other than race-ethnicity
and gender. Stratification on factors determined during
the patient interview, such as nicotine dependence, is not
practical in a busy hospital setting. The additional com-
plexity would add time to the patient encounter, poten-
tially disrupt patient care, and jeopardize recruitment.
Any variation in patient factors affecting quitting will be
evaluated in the statistical analysis. Combining data across
all CHART studies will also aid in the evaluation of quit
predictors across sites.
Study interventions
At each hospital, the patient’s tobacco-use history is
assessed at bedside by an admitting nurse and recorded
in the EMR. A TTS at each hospital reviews the EMR
for initial study eligibility (prescreening) prior to con-
ducting a bedside consult and screening visit. All study
participants receive a brief (10-minute) bedside tobacco-use evaluation and cessation consult that serves as the
usual care condition. All intervention service and medi-
cation use, both as an inpatient and after discharge, will
be tracked for all study participants. Internal evaluation
data indicate the use of outpatient cessation services and
medications following hospital discharge was extremely
rare (<1% of discharged smokers) among KPNW and
OHSU members.
We expect that about 15% of UC recipients will be
smoke-free at six months. Unpublished evaluation data
for hospitalized KPNW members and OHSU consult
recipients suggest about 15% of discharged patients will
remain abstinent six months after discharge. Stevens et
al. (2000) [10] reported a 14.6% quit rate for KPNW
hospitalized smokers receiving an intervention similar to
our usual care. We estimate that 23% of AR+ IVR recipi-
ents will be abstinent at six months, given an odds ratio
of 1.65, compared to UC recipients [3].
Inpatient tobacco cessation consult (usual care)
The usual care (UC) intervention provided by the TTS
involves a tobacco-use and quit history assessment, dis-
cussion of the health consequences of tobacco use and
benefits of quitting, and tailored discharge treatment
recommendations based on the patient’s tobacco history
and personal circumstances. Tobacco-use assessment
includes the types of tobacco used, amount used per
day, age at initiation, and use by other family members.
Quit history includes the number of past quit attempts
made, how long ago they last tried to quit, and their ex-
perience with using cessation programs and medications.
If they used medications, patients are asked about the
types of medications used (nicotine replacement therapy
[NRT], bupropion, varenicline), how they liked it, and if
they experienced any side effects. If appropriate, a tai-
lored discussion is provided of the relationship between
tobacco exposure and the patient’s diagnosis, and the
health benefits from remaining abstinent. Patients are
encouraged to remain abstinent after discharge and pro-
vided printed information about available outpatient
resources.
UC recipients are provided printed information and a
brief overview of existing counseling programs and FDA-
approved cessation medications that are typically covered
by the patient’s health insurance. UC patients are informed
about how to access available services on their own, that is,
the TTS does not actively assist the patient in enrolling in
a program or ordering medications.
At KPNW, patients access outpatient cessation ser-
vices and medications through the Health Education
Services (HES) department. Patients can enroll in
telephone-based and in-person counseling programs, or
an interactive web-based program, by contacting HES
on their own. Available medications include over-the-
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prescription bupropion and varenicline. KPNW patients
are charged a small copayment for the services they se-
lect, and must enroll in an approved counseling program
in order to receive medications at copay. Patients can
purchase cessation medications at discharge, typically
through the patient’s attending physician; however, the
patient will be required to enroll in a counseling pro-
gram through HES in order to get medications at copay.
At OHSU, patients are provided information about alter-
native counseling programs and available NRT products
(the patch, gum, lozenges, nasal sprays), bupropion, and
varenicline that are typically covered by insurance. Patients
are encouraged to call their insurance provider to deter-
mine cessation program coverage. Patients with Medicare,
Medicaid, or no insurance coverage are given information
about telephone counseling provided through the state quit
line (1-800-QUIT-NOW).
AR+ IVR Intervention
AR+ IVR assigned patients are assessed for interest and
willingness to enroll in stop-smoking services following
discharge. Those who express interest are helped to enroll
in available programs before leaving the hospital and staff
initiate discharge orders for cessation medications. At
KPNW, available programs include alternative telephone
counseling programs, individual and group classes, and an
interactive web-based program. All programs, except the
web-based program, have been shown to be effective at
helping smokers quit [9,15,18]. KPNW currently offers
nicotine replacement therapy (transdermal patches,
lozenges, gum), bupropion, and varenicline. OHSU partici-
pants will be offered enrollment in the Oregon Tobacco
Quit Line (OTQL) and provided information about avail-
able resources and medication options. Information about
study enrollment and recommended options for post-
discharge cessation treatment will be sent to each patient’s
primary source of health care via internal EMR notes or
external fax or electronic notes. At both sites, the out-of-
pocket costs for enrolled services are determined by parti-
cipants’ insurance coverage.
IVR follow-up calls
After discharge, AR+ IVR recipients receive four IVR
follow-up calls, at days 4, 14, 28, and 49 using Eliza Cor-
poration’s IVR system [19]. The call receipt window will
be +4 days for the initial call, and ±4 days for each sub-
sequent call. Participants are prompted for information
on current smoking status, cessation program enroll-
ment status, and assessment of cessation medication
use. Patients also receive brief, tailored, supportive mes-
sages to help them stay off cigarettes. These messages
include encouragement to enroll in cessation programs,
use cessation medications, or to speak to their doctor todetermine the best course of treatment. IVR alerts are
generated when a patient indicates that he/she would
like to speak to an OTQL quit coach or KP health coach
during the call. Study staff members facilitate a callback
from the respective coach.
Intervention fidelity
All research staff will be trained and certified in good clin-
ical practice. Prior to study implementation, all TTSs are
trained in how to deliver tobacco-dependence treatment
to hospitalized patients based on the OHSU model. TTSs
are also monitored during initial piloting and will partici-
pate in ongoing case management discussions. Other staff
will receive appropriate training in use of the study’s elec-
tronic data management system at each site and in coding
rules to complete the forms properly.
We monitor intervention fidelity by tracking inpatient
cessation service delivery, assisted referrals to outpatient
counseling and medications, notifications to primary
care providers, and EMR-documented and self-reported
cessation service use at follow-up. Inpatient counseling
is tracked by documenting TTS-patient interaction time,
and by documenting cessation topics discussed during
the consult. A treatment form is used to record TTS-
patient discussion of tobacco use and quitting history,
past cessation service and medications use, current in-
patient NRT dispenses and comfort, risk factors for
maintaining abstinence, medical contraindications for
medication use after discharge, interest in remaining ab-
stinent after discharge, and outpatient treatment recom-
mendations provided. The intervention protocol and
treatment form do not specify that a particular topic
order must be followed by the TTS. Instead, the form is
completed based on topics discussed. Treatment data
are recorded and monitored for completeness and add-
itional training conducted as needed.
For study participants randomized to the AR+ IVR con-
dition, we obtain documentation of assisted referral out-
come (acceptance/refusal of referral, discharge medication
ordered), primary care/usual care provider notification
completed, and IVR enrollment. Outpatient intervention
use for all enrolled participants is obtained during the
study period from EMR records and from patient self-
reports at follow-up. The IVR intervention is provided via
a standard IVR automated calling system for participants
at both sites. The content for each call is standard for both
hospitals, with some site-specific tailoring. Each call uses
branching logic based on information provided from the
previous call to gather more accurate and personalized
information.
Safety monitoring plan
Behavioral counseling and FDA-approved cessation
medications are considered low-risk interventions for
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with medication use are well known, for example, skin
rashes, irritability. In some instances, serious adverse
events (SAEs) linked to increased risk of suicide have
been documented among bupropion and varenicline
users [20-22]. This trial involves patients hospitalized for
potentially serious health conditions, which increases the
risks of re-hospitalization or death.
This study follows the CHART DSMB recommenda-
tions, and KPNW and OHSU IRB policies, for tracking
and reporting SAEs and AEs. An adverse event tracking
and reporting system is used to monitor expected and
unexpected SAEs and AEs reported by participants at
six- and twelve-month follow-up. The principal investi-
gator or medical monitor will review reported events to
determine if they are study-related. Unexpected or po-
tentially study-related AEs and SAEs, including confi-
dentiality breaches, will be reported to the local IRBs
within forty-eight hours of identification, and to the
DSMB within seven days. SAEs and AEs that are not
study-related will be reported to the DSMB every six
months and to the local IRBs every twelve months.
Study measures
Intervention delivery and data collection occur at an
inpatient tobacco-cessation consult and screening/
recruitment visit, postdischarge IVR telephone calls
(AR+ IVR only), in-person follow-up interview at six
months postrandomization, and during a telephone
interview at twelve months. Procedures are standardized
as much as possible between the two settings in order to
avoid confounding differences in recruiting methods due
to site differences. Furthermore, the primary and sec-
ondary outcomes for this study have been harmonized
with other CHART studies following recommendations
of the CHART DSMB.
Primary outcome
The primary outcome for the I-TSAR study is self-
reported thirty-day abstinence from cigarettes at six
months postrandomization for AR+ IVR compared to
UC. Data on days since the last cigarette (even a puff )
are collected from participants at six- and twelve-month
follow-up assessments. The number of days since the
last cigarette was smoked allows calculation of seven-
day, thirty-day, and continuous abstinence as secondary
outcomes. Biochemical validation of self-reported abstin-
ence is obtained at six months and reported as an
additional outcome. All participants are given an exhaled
carbon monoxide assessment at the six-month in-person as-
sessment using a Bedfont Smokerlyzer Carbon Monoxide
Monitor (Bedfont Scientific Ltd., Maidstone, Kent, UK) [23].
Self-reported abstinence of ≥7 days is verified by a CO level
≤8 parts per million (ppm). For comparison with otherCHART studies, self-reported quitting is confirmed using a
salivary cotinine (NicAlert) test strip (Nymox Pharmaceutical
Corp., Hasbrouck Heights, NJ, USA). Salivary cotinine meas-
urement of ≤50 ng/ml confirms abstinence [24]. Self-
reported quitters using nicotine replacement products at the
time of the six-month assessment will be considered as ‘con-
firmed quitters’ by a CO level of ≤10 ppm.
Power
A 2:1 ratio of AR+ IVR to UC for 900 randomized partici-
pants will provide adequate power to detect an eight per-
centage point difference in thirty-day point prevalence
abstinence at six months (our primary outcome), assuming
an unbiased method of assigning an outcome to nonre-
spondents. The unbalanced design requires 864 partici-
pants to achieve 80% power, with two-tailed α set at .05, to
detect a difference in thirty-day abstinence of eight per-
centage points between treatment groups. We expect the
UC group will achieve a 15% abstinence rate, based on
analyses of EMR data (unpublished) for similar populations
at each site. An odds ratio of 1.65 for patients with >30
days of follow-up [3] results in a 23% expected abstinence
rate for the AR+ IVR group. The power calculations were
conservative [25-28] and no continuity correction was ap-
plied. Rounding up to 900 total participants added an add-
itional measure of conservatism.
Additional tobacco measures
For participants reporting having smoked during the
follow-up period, we assess amount smoked per day,
and the first two consecutive days smoked postdischarge,
to calculate relapse curves by group assignment. We also
collect baseline and follow-up information about other
tobacco use, including cigars, pipes, bidis, hookahs, and
smokeless tobacco to control for substitution. We ask
about other household smokers and indoor smoking
rules.
Intervention dose
We collect inpatient and outpatient smoking cessation
counseling and medications provided and used by study
participants from the initial inpatient consult through 12-
month follow-up. Measures collected are used to assess
treatment fidelity and to assess an intervention dose re-
sponse on the primary outcome. Inpatient treatment mea-
sures include: TTS counseling time and content checks;
medication dispenses; quit materials provided; and in-
patient referrals to outpatient services (counseling pro-
grams and medication orders). These data are collected
from TTS and EMR data sources. Outpatient treatment
measures include: counseling program enrollment and par-
ticipation, such as telephone quitlines, in-person individual
and group programs, and web-based programs; FDA-
approved prescription and over-the-counter medications
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gum, lozenges, and sprays. Medications provided and used,
including combination therapy, will be assessed from EMR
records and participant self-report.
Intervention resource costs
We collect tobacco cessation intervention delivery costs
for study participants from the initial inpatient consult
through 12-month follow-up. Cost data are obtained to
support analyses from participant, health system/insurer,
and societal perspectives assuming an opportunity cost
approach to resource valuation. Source of payment for
each expense will be used to assign costs. Intervention
costs we use in the study include: TTS inpatient prescre-
ening time; TTS patient contact time; inpatient medica-
tion dispenses; outpatient cessation counseling and
medication costs; printed quit materials; IVR follow-up
costs; patient travel expenditures for cessation treatment;
and patient lost time from work for treatment and
hourly earnings. Health system costs we use include:
TTS and other staff training time; program management
time; new materials development and supplies; and in-
ternal feedback reporting.
Health-care utilization and expenditures
We collect health-care utilization data beginning with
the initial hospitalization through 12-month follow-up.
Data include: encounters by type (primary care, emer-
gency department, urgent care, hospital admissions);
length of hospital stay (initial and subsequent hospitaliza-
tions); discharge diagnoses (ICD-9); procedures (CPT-4);
pharmacy dispenses and NDC codes; diagnostic-related
groups; and medical records data for health-care expendi-
tures (actual costs based on relative-value units and paid
claims; retail costs for medications) by source of payment.
Data are used to assess differences in utilization and
expenditures by treatment group.
Health-related quality of life
We obtain patient responses from the EuroQual (EQ5D-
5L) [29-31] at baseline and six- and twelve-month
follow-up for assessing changes in health-related quality
of life for AR+ IVR versus UC participants during the
study period. Responses are combined with remaining
life expectancy data for current and former smokers [32]
to estimate differences in expected quality-adjusted life
years saved by treatment group.
Other patient information
Age, sex, ethnicity, race, height, weight, marital status,
educational attainment, annual income, insurance cover-
age, time after waking before first cigarette, confidence
for successful quitting, Patient-Health Questionaire-2
depression screen, and the Audit-C alcohol screen, arecollected at baseline for primary and secondary outcome
analyses. Weight is collected at follow-up.
Data analysis
This section describes the methods used to evaluate the
specific aims of the I-TSAR study. The primary aim for this
study has been harmonized with the other NIH-funded
CHART collaborative group studies and approved by the
CHART DSMB.
Specific Aim 1: estimate self-reported thirty-day abstinence
at six and twelve months for patients assigned to receive
inpatient AR + IVR compared to usual care
Based on KPNW and OHSU member data and meta-
analyses of effectiveness of hospital cessation programs
with ≥1 month postdischarge follow-up, we expect about
15% of usual care patients and 23% of AR+ IVR partici-
pants will be abstinent six months following discharge.
The primary analysis assumes that nonrespondents are
smokers.
The treatment effect on the primary outcome (and
other binary outcomes) will be evaluated using logistic
regression, logit[Yik] = β0 + β1Xk + e ik (Model 1), where
Yik is the binary indicator of the observed binary smok-
ing status for the ith patient (i = 1,. . .,nk) within the k
th
treatment condition (k = 1,2), Xk is the fixed effect of the
kth condition, that is, intervention or control, and β0, β1
are parameters to be estimated. Any difference between
the predicted and observed values is left to the residual
error (e ik) in this model. Multiple regression methods
available in SAS PROC Logistic [33] will be used to esti-
mate the parameters of this generalized linear model.
The intervention fixed effect will be tested using the
score χ2 test.
Model 1 specifies only one source of systematic vari-
ation among the trial conditions, Ck. Any factor other
than the intervention that favors one condition over the
other serves to bias the estimate of the intervention ef-
fect. Since this is a randomized trial, there are no differ-
ences expected between treatment and control arms in
the distribution of covariates. However, there might be
unmeasured factors at the various sites that might result
in varying effect sizes between the two arms. These fac-
tors are potentially confounded with site. In the adjusted
analysis, site, interaction between site and treatment,
and measured covariates are added to the analysis to re-
duce confounding and to improve the precision of the
estimate of the intervention effect. Covariates can be
measured at the site or patient level. Covariates measured
at the group (site) level and patient level are distinguished
as G and M. With covariates at two levels and patients
nested within sites, we shift to a two-level generalized lin-
ear model with logit link. Level 1 involves patient-level
variables: logit Yick½  ¼ β0c þ β1cXk þ β2cMi þ eick , where
Fellows et al. Trials 2012, 13:129 Page 10 of 13
http://www.trialsjournal.com/content/13/1/129Mi is a vector of patient-level covariates (bold indicates a
vector throughout this section), β0c, β1c, and β2c are
patient-level parameters that are allowed to vary over sites,
and c = 1, . . ., C clinical sites, and eick is the residual.
The level-1 model implies three level-2 equations to
model variation between sites in patient-level parameters
and adds the effect of site-level covariates:
where γ0., γ1., γ2 are parameters to be estimated, Sc is
the vector of c-1 site indicators, Gc is the vector of site-
level covariates, and u are residual terms. The resulting
combined two-level model is of the form:
logit Yick½  ¼ γ00 þ γ01Scþ γ02Gcþ u0c
þ γ10þ; γ11Sc;þ; γ12;Gc;þ; u1c½ Xk
þ γ20þ; γ21Sc;þ; γ22;Gc;þ; u2c½ Mi þ eick;
that simplifies to (Model 2):
logit Yick½  ¼ γ00 þ γ01Scþ γ02Gcþ γ10 þ u1c½ Xk
þ γ11ScXk þ γ12GcXk þ γ20 þ u2c½ Mi
þ γ21ScMi þ γ22GcMi þ u0c þ eick;
where combined effects, for example, ScXk, indicate an
interaction. Not shown here are the multiple slope coef-
ficients on the vectors of M and G covariates. We will
test the assumption of linear relationships between
quantitative covariates and the logit of smoking status
by adding quadratic terms to Model 2. The test of
homogeneity of covariate regression slopes across condi-
tions and sites is the test that the associated parameter
(for example, γ11) is 0. When the covariates were mea-
sured at baseline, this is a test of whether the variable
moderates treatment response. This could provide useful
information on subgroups of smokers for whom the
intervention is more or less effective.
Covariates and effect modifiers
Group-level covariates considered for the analysis in-
clude site (KPNW and OHSU), insurance type, inpatient
care unit, smoking cessation program used, and medica-
tions used. Individual-level covariates include age, sex,
ethnicity and race, marital status, amount smoked per
day, time to first cigarette, stage of readiness, depression
screen positive, alcohol abuse screen positive, socioeco-
nomic status (income, education), and other smokers in
the household. Though power will be limited, we will re-
port treatment effects for race/ethnicity categories and
by sex.
Secondary analyses will use self-reported seven-day
and continuous abstinence at six and twelve months,
biochemically confirmed seven-day abstinence at six
months, number of quit attempts during the prior year
(modeled as Poisson), and amount smoked among con-
tinuing smokers (modeled as Poisson).Specific Aim 2: estimate the dose effect on smoking
abstinence at six and twelve months for the AR+ IVR
compared to usual care
Variation in outpatient service use is used to assess a
dose–response effect for cessation services. We test the
hypothesis in two ways using the model developed for
Specific Aim 1. First, we will include only AR+ IVR reci-
pients and redefine X as a multilevel ordinal variable
representing intervention dose (Dr) ranging from no
postdischarge intervention to full intervention. The
number of levels to Dr will be determined using a rank
scoring algorithm that includes cessation service pro-
gram enrollment and completion, cessation medications,
and number of IVR follow-up calls received. Additional
inputs will be considered based on actual study data.
Second, we will rerun the analysis including control
group participants with a dose score using the same
method. For each analysis, we will conduct trend tests
and assess the presence of a dose threshold.
Specific Aim 3: estimate total and mean costs per
participant for AR + IVR and UC recipients, and, the
incremental cost-effectiveness of AR + IVR at six and twelve
months compared to UC from health plan/insurer and
societal perspectives
We hypothesize that AR+ IVR is a cost-effective strategy
at six and twelve months for smoking cessation com-
pared to UC from societal, health plan/insurer, and indi-
vidual patient perspectives. Assuming the intervention is
effective, we calculate the incremental net cost per add-
itional quit for AR+ IVR recipients compared to UC,
and incremental costs per quality-adjusted life-years
saved (QALYs).
Total intervention costs and costs per participant for
AR+ IVR and UC are evaluated. All resource costs used
to implement and deliver the inpatient and post-
discharge follow-up services, counseling programs, med-
ications, and IVR calls are included in the cost
calculations. The incremental net cost is calculated per
additional quit for AR+ IVR participants compared to
UC participants, and incremental costs per quality-
adjusted life-years saved (QALYs) [34,35]. Program cost
analysis (PCA) is used to assess the actual economic, or
opportunity, costs incurred to produce the outcome
observed from the AR+ IVR and UC interventions. The
value and the incremental resources required for the
intervention for the health system/insurer and societal
perspectives are identified. Individual-level cost data are
collected to enable variance estimation for the average
cost estimates. Total intervention costs and costs per
participant for AR+ IVR and usual care recipients are
estimated.
Abstinence and cost data are used to calculate the in-
cremental net cost per additional quit for AR+ IVR
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total costs and cost per participant, by payment source
are reported. Incremental cost-effectiveness ratios
(ICERs) are measured as: a) incremental intervention
costs per incremental quit from health plan/insurer and
patient perspectives; b) incremental total costs (interven-
tion plus health care expenditures during follow-up) per
incremental quit from health system/insurer and patient
perspectives; c) incremental intervention costs per incre-
mental quality-adjusted life-year (QALY) saved from a
societal perspective; and d) incremental total costs
(intervention plus health-care expenditures during
follow-up) per incremental QALY saved from a societal
perspective. QALYs for each intervention arm are esti-
mated using life expectancy data and responses from
interviewer-administered EQ5D-5L.
Specific Aim 4: evaluate health care utilization at twelve
months for AR+AVR and usual care
We measure health-care utilization for AR+AVR com-
pared to UC by the mean number of combined out-
patient and inpatient encounters (visits) per participant
during follow-up. This aim is addressed using participant
survey responses and medical records (electronically for
those receiving care at KPNW and OHSU facilities). For
AR+ IVR compared to UC, we measure health-care
utilization by the mean number of combined outpatient
and inpatient encounters (visits) per participant during
follow-up. This aim will be addressed using participant
survey responses and medical records (electronically for
those receiving care at KPNW and OHSU facilities). The
functional form of models 1 and 2 for the primary aim
will be restated within a Poisson regression model struc-
ture and analyzed using SAS PROC GENMOD, specify-
ing a log link function and Poisson distribution.
Health-care utilization data are regularly characterized
by nonnormal distributions. While zero values are not
expected for visits in the study population, there may be
substantial variation in the number of visits completed.
Depending on the number of inpatient visits, analysis of
the number of inpatient days separately from outpatient
visits may be conducted. If the variance is greater than
the mean, we will control for the impact of overdisper-
sion by including a term in the model for the unob-
served heterogeneity of each ith observation. If data
allow separate modeling of inpatient days, the large
number of zero stays will require specifying a zero-
inflated negative binomial model.
Sensitivity and threshold analyses
Sensitivity of cost-effectiveness ratios to key parameters:
intervention acceptance, intervention costs, abstinence
rate, discount rate, pharmacotherapy use and costs, and
QALYs saved are measured. Threshold analyses for keyparameters are used to identify input levels that alter
conclusions. The cost-effectiveness analysis above
reflects a deterministic approach using standard univari-
ate and multivariate sensitivity analyses to test the ro-
bustness of the results. Based on the results of these
analyses, probabilistic sensitivity analyses will be consid-
ered, but only if the standard sensitivity tests are unclear
or not informative [36-39].
Missing and incomplete data
Nonresponse is defined as when a participant is lost to
follow-up or refuses to answer questions about their
smoking status. For our primary hypothesis test, we as-
sume participants lost to follow-up are smokers. De-
pending on actual follow-up rates achieved, the results
may be presented using recommended new strategies
[40] to deal with missing data. Characteristics associated
with nonresponse in smokers are used with SOLAS and
SAS programs for implementing multiple imputation
procedures. A complete record of subject assignment
and attrition will be included in published reports of this
trial. For subject attrition, the type of attrition (that is,
‘lost to follow-up’, ‘deceased’, and ‘refused to continue
participation’) is monitored. An attempt will be made to
identify the causes of missing data. If smokers are more
likely than nonsmokers to be lost to follow-up or to be
refusals, then nonresponse is ‘nonignorable’ (that is,
nonresponse is related to the value of the smoking vari-
able that would have been observed).
A large proportion of the study population will have
had a major adverse health event. Thus, the number of
patients deceased at follow-up may be higher than is
typical in other smoking cessation studies. Patients
deceased before follow-up will be excluded from the pri-
mary outcome analyses. We will identify the number of
deceased patients in the consort table. We may include
deceased patients in the economic evaluation because of
the high cost of end-of-life care. In the cost-effectiveness
analyses, we will evaluate deceased patients as smokers
(treatment failures) and assign them a health-related
quality of life value of 0. We will also use analytic meth-
ods that account for censoring for patients with limited
health-care utilization data. For example, for KPNW par-
ticipants who leave the plan after several months, and for
whom we are unable to obtain medical records and
expenditures for the entire follow-up period, will have
their encounter (visit) and expenditure data for the entire
follow-up period annualized based on the proportion of
the year for which they were enrolled in the heath plan.
Discussion
Effective and cost-effective approaches to bridging in-
patient and outpatient tobacco dependence treatment can
be an important part of health system efforts to improve
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study provides estimates of the health impacts, and eco-
nomic impacts, of a practical approach to help smokers
remain abstinent after hospital discharge. Our interven-
tion protocol, providing brief inpatient cessation counsel-
ing, assisted referral to effective outpatient counseling and
medications, and IVR follow-up over a seven-week period,
is in line with the findings from a recent Cochrane meta-
analysis showing that smokers with four or more weeks of
cessation support after discharge were 1.65 (CI 1.44–1.90)
times more likely to quit successfully after a year com-
pared to those without support [3]. We expect to see a
similar relationship between the AR+ IVR and UC groups,
but also expect a dose–response for participants based on
the number of cessation services used (counseling sessions
and medication days). Our 2:1 randomization strategy will
allow us to evaluate the relationship between intervention
dose and outcome.
The setting for this study provides an opportunity to
compare study outcomes in two different health systems,
a large comprehensive managed care organization and a
large academic hospital. Since KPNW is a closed system,
we expect the integration of inpatient and outpatient care
to be more efficient there because of the ease of access to
patient medical records and streamlined communications
between inpatient medical staff, pharmacy staff, and out-
patient care providers. Determination of plan benefit
levels (for example, copays, medication availability) is also
readily available. OHSU has a diverse patient population.
Linking inpatient and outpatient care will be more com-
plicated for OHSU participants since many patients do
not have a regular health-care provider or are uninsured
and receive outpatient care from providers or clinics out-
side of the OHSU system. Informing these providers about
their patients’ cessation attempts will be more difficult.
Also, access to services may vary based on differences in
insurance coverage. We will evaluate whether these sys-
tem differences affect treatment outcomes.
The ultimate goal of this study is to permanently
integrate a practical tobacco cessation program into the
participating health-care systems. This effort requires
an understanding of the economic, logistical, and
organizational challenges faced by each organization. To
be effective in the real world, an intervention must inte-
grate easily into the existing clinical workflow and become
an integral part of the health plan’s normal functioning.
To accomplish this, we use Bracht’s five-stage community
organization model [41] to guide our support-building ac-
tivities within each organization. We identify key stake-
holders at each institution who are working with study
staff to ensure that the intervention protocol fits the
needs, resources, and values of the organization. We will
share intervention recruitment, delivery, and acceptance
measures with stakeholders using periodic clinic feedbackreports. Performance measures relevant to each institution
will help the program make the transition from a novel
intervention to standard care at each organization. In
addition, the I-TSAR investigators will provide data on
intervention reach, effectiveness, and cost analyses to sup-
port financial decisions and commitments.
Trial status
The I-TSAR study is currently recruiting participants.
Recruitment began in November 2011, and is expected
to conclude in May 2013.
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